Drinking more coffee may significantly reduce a person’s risk of prostate cancer, with a nearly 1% lesser likelihood seen with each additional daily cup of coffee consumed, an analysis of published studies suggests. “Coffee consumption and risk of prostate cancer: a systematic review and meta-analysis” was published in BMJ Open. Coffee contains a number of biologically…
The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication will be available through the Cancer Drugs Fund (CDF), a funding program that seeks to increase access to promising cancer medicines in…
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and Radiological Health, part of the U.S. Food and Drug Administration (FDA). The technology — known fully as the Imagio Breast Imaging System — was designed to help physicians better distinguish malignant, or cancerous breast tumors…
Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study will investigate UV1, in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib), as a…
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data from the trial (NCT03933735), which continues to recruit participants in the U.S., showed an 80% overall response rate at doses of 40 mg or more, with…
First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver cancer — according to updated data from an ongoing Phase 3 trial. The latest findings from the study, called IMbrave150 (NCT03434379), showed that the combination therapy…
Offering Black men active surveillance to manage low-risk prostate cancer is safe and does not increase the risk of disease spreading or death more than it does for white men, a study has found. However, Black men on active surveillance are more likely to progress and require definitive treatment, researchers said, and further investigation is needed…
A less-frequent, fixed dose regimen of Imfinzi (durvalumab) has been approved in the European Union and U.K. to treat adults with locally advanced, inoperable non-small cell lung cancer (NSCLC), announced the therapy’s developer, AstraZeneca. This new dosing option, which will reduce the need for medical appointments, will be available to NSCLC patients weighing more than…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from certain fees, trial protocol assistance, and seven years…
Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The findings suggest that an eight-week mindfulness intervention can reduce activity in parts of the brain related to pain and to emotional reactivity (having a heightened emotional response to something unpleasant). The study, “Reduced Emotional Reactivity…
